Can Chinese Phase I data from the West accelerate China drug development?

The science of ethnobridging – a way to implement cost-effective, multi-ethnic approaches to global clinical trial research and drug development.


Open PDF

Return to Insights Center

Related Insights

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Blog

Best practices and lessons learned in a challenging IBD study

Jul 19, 2023

Blog

New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure

Jan 13, 2023

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Blog

To build a state-of-the-art oncology site network, we went back to basics

Mar 3, 2025

Article

Australia: Infrastructure and Innovations for Clinical Trials

Aug 28, 2023

Blog

CNS Summit Recap: The Future is Collaborative

Nov 22, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Related Insights

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Blog

Best practices and lessons learned in a challenging IBD study

Jul 19, 2023

Show more